Anaphylaxis post-COVID 19 vaccinations in Singapore

Peck et al discuss their study on anaphylaxis post-COVID 19 vaccinations in Singapore. Anaphylaxis was the first serious adverse event (AE) of special interest following COVID-19 vaccination to have surfaced in Singapore. Locally, individuals who developed physician-diagnosed anaphylaxis or severe allergic reactions to the mRNA vaccines would be medically ineligible for mRNA vaccines and offered non-mRNA vaccines as alternatives. Hence, patients who received heterologous vaccination were expected to largely comprise such at risk individuals and it will be of interest to review these patients further. The results revealed that anaphylaxis is a rare but serious AE following COVID-19 vaccination. The outcomes of anaphylaxis can be mitigated with timely medical intervention. The review of the anaphylaxis cases helped to guide vaccination strategies and adds to the cumulative knowledge of heterologous vaccination, in particular in persons with multiple allergies.